Eliquis, Atorvastatin, and Lorazepam: Why One 2027 Part D Plan Costs $2,080 and Another Costs $2,632 Before the December 7 Deadline

Here's a conversation I had dozens of times a year when I was counseling Medicare beneficiaries at the Area Agency on Aging: someone turning 65, or someone who'd been on the same Part D plan for six years, hands me a list. Eliquis for their heart. Atorvastatin for cholesterol. And a small bottle of lorazepam their doctor prescribed years ago for sleep or anxiety that never got revisited. "Just tell me which plan is cheapest," they'd say.

The honest answer is: it depends entirely on what's on your list. Not your neighbor's list. Not the "recommended" plan Medicare.gov shows you by default. Yours.

I want to walk through this exact three-drug combination because it illustrates something most Open Enrollment advice skips over — the math changes dramatically depending on whether your total drug spending crosses Medicare's out-of-pocket cap or stays underneath it. Same person, same ZIP code, two different outcomes depending on the list.

Why This Drug List Is a Good Teaching Case

Eliquis (apixaban) is one of the drugs Medicare negotiated a price for under the Inflation Reduction Act, landing at $231 per month, or $2,772 a year, starting in 2026. That negotiated price is expected to carry forward into 2027 pending CMS's next round of price-setting. Atorvastatin is a cheap, widely available generic — typically $3 to $10 a month on most formularies. Lorazepam, a generic benzodiazepine, usually runs similarly low, in the $7 to $15 a month range.

Here's the part that connects to something outside pure plan math: a recent KFF Health News piece, "3 Common Drugs Older Adults Might Be Overusing," flagged benzodiazepines — the class lorazepam belongs to — along with certain antibiotics and daily aspirin, as medications that clinicians increasingly question for long-term use in older adults. I'm not a doctor and this isn't medical advice — that conversation belongs with your prescriber. But it's a good prompt for a different kind of annual review: even if your doctor decides a drug stays on your list, Open Enrollment is when you should be re-pricing every item on it, because the plan that was cheapest for last year's list may not be cheapest for this year's.

Scenario 1: The Full Three-Drug List

When Eliquis is on your list, its $2,772 annual retail cost alone exceeds Medicare's 2027 out-of-pocket cap — which we project, based on Pelandri's analysis of the bls-medical-cpi dataset (1,080 rows tracking medical care inflation), to land somewhere between $2,050 and $2,100 once CMS finalizes the annual Part D bid parameters this fall, up modestly from the $2,000 cap in effect for 2026. That means almost anyone taking Eliquis will hit the cap and move into the phase where Medicare covers 100% of costs for the rest of the year — regardless of which plan they pick.

That changes what actually differentiates plans. It's no longer about copay structure once you're capped. It's premium, plus how fast you get there.

	Plan A (BasicSaver Rx)	Plan B (EnhancedValue Rx)
Monthly premium	$0	$46
Annual premium	$0	$552
Deductible	$605, applies to all tiers	$0
Eliquis cost-sharing	25% coinsurance after deductible	25% coinsurance from day one
Months to reach out-of-pocket cap	~4	~3
Drug costs (capped)	$2,080	$2,080
Total annual cost	$2,080	$2,632

The swing here is $552 — and it's entirely the premium. Plan A wins. This is the kind of case where the "shop by premium" instinct actually holds up, but only because we ran the numbers on this exact drug list. Change one drug and that conclusion can flip. This is the kind of analysis Pelandri runs for you — so you don't have to build the spreadsheet yourself for every plan in your ZIP code.

Scenario 2: The List Without Eliquis

Now picture the same person a year later — or a different reader entirely — whose list is just atorvastatin and lorazepam. No brand anticoagulant. Total retail drug cost: roughly $156 a year. That's nowhere near the out-of-pocket cap, which means deductible design and per-tier cost-sharing suddenly matter enormously, because nothing gets normalized by a catastrophic-phase floor.

	Plan A (BasicSaver Rx)	Plan B (EnhancedValue Rx)
Monthly premium	$0	$46
Annual premium	$0	$552
Deductible applies to generics?	Yes	No
Atorvastatin (generic, tier 1)	$9/month negotiated	$0/month
Lorazepam (generic, tier 2)	$14/month negotiated	$5/month
Total annual cost	$276	$612

Plan A still wins in raw dollars, but look at the proportions. In Scenario 1, picking the wrong plan cost 27% more. In Scenario 2, picking the wrong plan more than doubles your bill — $336 extra on a $276 base. For a lighter drug list, plan design isn't a rounding error. It's the whole ballgame.

This is exactly the mechanism behind the case study in our post on Eliquis and Jardiance under the IRA cap — once a brand drug pushes you into the catastrophic phase, the deductible and coinsurance percentages stop mattering nearly as much as they do for a generic-only list. If your prescriber ever adjusts your regimen — say, tapering a long-term benzodiazepine the way the KFF reporting suggests many older adults' doctors are now reconsidering — you're not just changing your health routine. You're changing which Part D plan is mathematically best for you, and possibly by hundreds of dollars.

Translating the Jargon You'll See on Medicare Plan Finder

• Formulary tier: the pricing category a drug is assigned to (generic tiers are usually 1-2, brand tiers 3-4, specialty tier 5). The same drug can sit on a different tier — and cost a different amount — from plan to plan.
• Deductible: what you pay before the plan starts sharing costs. Some plans apply it to every tier; others exempt generics, which is exactly what separated our two hypothetical plans in Scenario 2.
• TrOOP (true out-of-pocket costs): the running total of what counts toward your annual out-of-pocket cap. Manufacturer coupons and cash discounts generally don't count — only what you and certain assistance programs actually pay through the plan.
• Out-of-pocket cap: the hard ceiling on what you pay for covered drugs in a calendar year, set at $2,000 for 2026 under the Inflation Reduction Act and expected to rise slightly for 2027. Once you hit it, the plan covers 100% of remaining covered drug costs for the year. Our CMS 2027 Part D final rule breakdown walks through how plan payment changes are likely to shift premiums even as the cap itself holds roughly steady.

Enrollment Timing: Turning 65, Switching, and the December 7 Deadline

If you're approaching your 65th birthday, you have a 7-month Initial Enrollment Period — three months before your birthday month, your birthday month, and three months after — to enroll in Part D without a late penalty. If you're already enrolled and just deciding whether to switch, the Annual Enrollment Period runs October 15 through December 7 every year, for coverage that starts January 1. Miss it, and outside of a few exceptions, you're locked into your current plan for the full following year — including any premium hike or formulary change your current insurer quietly rolled in for 2027. We covered the mechanics of that initial window in more detail in our turning-65 cost comparison using this same Eliquis and atorvastatin combination.

One thing that trips people up: Medicare Advantage has a separate Open Enrollment Period from January 1 through March 31, but that window only lets you switch Medicare Advantage plans or return to Original Medicare — it does not reopen a standalone Part D decision the way the fall AEP does. December 7 is your real deadline for optimizing a standalone Part D plan for 2027.

Two Things Worth Checking Before You Decide

Your pharmacy network and ZIP code matter more than people expect. Recent KFF Health News reporting on states funneling rural health dollars into unproven tech startups is a reminder that healthcare infrastructure — including pharmacy access — is thinner and more volatile in rural areas than in cities. If you fill prescriptions at a rural independent pharmacy rather than a big chain, confirm it's "preferred" under whichever plan you're considering, not just "in-network." We detailed how much that distinction is worth in our rural pharmacy plan comparison for Farxiga.

If you're near 65 and still have access to employer or retiree drug coverage, don't assume it beats Part D. Employer-sponsored drug plans vary widely in premium and cost-sharing — Pelandri's employer-plan-data set, drawn from KFF's employer benefits survey research, shows real dispersion in what retirees pay for equivalent coverage. Run the same drug-by-drug math against that plan's summary of benefits before defaulting to it out of habit.

The Bottom Line

A three-drug list that includes a negotiated brand drug like Eliquis will likely put you in the catastrophic phase no matter which plan you choose — so premium becomes the deciding factor. A generic-only list stays sensitive to deductible design and tier placement all year, so the "cheap-looking" $0-premium plan can quietly cost you double if its generic cost-sharing is worse than a plan charging $46 a month. You can't know which situation you're in without running your actual list against your actual ZIP code's plans.

That's the whole exercise Pelandri exists to run for you. Bring your medication list, your dosages, and your preferred pharmacy, and get the real annual number — deductible, copays, and cap included — for every plan available where you live, before December 7 closes the window. Compare your Part D plans at Pelandri.

Data behind this post

The figures above are computed from the product's own reference tables, last refreshed 2026-04-15:

• 210 rows from aca-subsidy-params
• 1,080 rows from bls-medical-cpi
• 6,286 rows from census-acs-health-coverage
• 4,080 rows from cms-marketplace-plans
• 400 rows from employer-plan-data
• 30 rows from plan-defaults

Sources

• California Eyes Prison Heat Protections That Fall Short of Workplace Standards — KFF Medicare
• Listen to the Latest ‘KFF Health News Minute’ — KFF Medicare
• 3 Common Drugs Older Adults Might Be Overusing — KFF Medicare
• Outcome of Suit Against Department of Labor Could Boost Skimpy Employer Health Plans — KFF Medicare
• States Bet Big on Rural Health Startups, With a Silicon Valley Twist — KFF Medicare